Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Globus Medical Inc. Class A (GMED)

NYSE: GMED · Surgical & Medical Instruments & Apparatus · Audubon, PA

Our rating: Positive

Positive reaffirmed at $71.05, moderate conviction, November 6, 2026.

Breaks if: The Positive view is invalidated if reported revenue growth falls below 6% in two consecutive quarterly prints over the next 12 months — the level at which post-merger base effects would have fully normalized and an underlying organic deceleration would be exposed. Separately, if trailing free-cash-flow margin drops below 14% within four quarters, the valuation anchor built on robust cash conversion no longer holds.

Key figures

Market value$9.0B
Revenue, last 12 months$3.1B
Net income, last 12 months$558M
Free cash flow, last 12 months$767M
Price to earnings16.1×
Free cash flow yield8.5%
Dividend yield0.0%
Operating margin21.6%
Return on equity12.1%
Beta to the S&P 5000.93
Volatility, annualized43.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$764M−0.7%$1.04$225M
June 30, 2026$790M5.9%$1.10$177M
March 31, 2026$760M27.0%$0.90$163M
December 31, 2025$826M25.7%$1.02$202M
September 30, 2025$769M22.9%$0.88$214M
June 30, 2025$745M18.4%$1.49$31M
March 31, 2025$598M−1.4%$0.54$141M
December 31, 2024$657M6.6%$0.19$193M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

12 ledger entries and 35 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.